相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
Shinichiro Kashiwagi et al.
PLOS ONE (2017)
Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
Shinichiro Kashiwagi et al.
BMC CANCER (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study
Takahiro Toyokawa et al.
BMC CANCER (2016)
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
Shigeto Ueda et al.
BRITISH JOURNAL OF CANCER (2016)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schoffski et al.
LANCET (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
Hidemi Kawajiri et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
New metastases are associated with a poorer prognosis than growth of preexisting metastases in patients with metastatic breast cancer treated with chemotherapy
Christopher Twelves et al.
BREAST CANCER RESEARCH (2015)
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
T. Yoshida et al.
BRITISH JOURNAL OF CANCER (2014)
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
Yasuhiro Funahashi et al.
CANCER SCIENCE (2014)
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
Saskia Litiere et al.
EUROPEAN JOURNAL OF CANCER (2014)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment
Muhammad Zaeem Noman et al.
CANCER MICROENVIRONMENT (2014)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
Jose R. Rossari et al.
JOURNAL OF ONCOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inflammation, a key event in cancer development
HT Lu et al.
MOLECULAR CANCER RESEARCH (2006)
分享论文
